These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 28460083)

  • 21. Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.
    Strand V; Kremer JM; Gruben D; Krishnaswami S; Zwillich SH; Wallenstein GV
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):592-598. PubMed ID: 27565000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis: Pooled efficacy and safety analyses.
    Lomonte ABV; Radominski SC; Marcolino FMD; Brenol CV; Zerbini CAF; García EG; Akylbekova EL; Rojo R; de Leon DP
    Medicine (Baltimore); 2018 Aug; 97(31):e11609. PubMed ID: 30075534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modelling the cost-effectiveness of tofacitinib for the treatment of rheumatoid arthritis in the United States.
    Claxton L; Taylor M; Gerber RA; Gruben D; Moynagh D; Singh A; Wallenstein GV
    Curr Med Res Opin; 2018 Nov; 34(11):1991-2000. PubMed ID: 29976110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data.
    Takeuchi T; Yamanaka H; Yamaoka K; Arai S; Toyoizumi S; DeMasi R; Fukuma Y; Hirose T; Sugiyama N; Zwillich SH; Tanaka Y
    Mod Rheumatol; 2019 Sep; 29(5):756-766. PubMed ID: 30489177
    [No Abstract]   [Full Text] [Related]  

  • 25. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
    Kremer J; Li ZG; Hall S; Fleischmann R; Genovese M; Martin-Mola E; Isaacs JD; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Riese R; Bradley J
    Ann Intern Med; 2013 Aug; 159(4):253-61. PubMed ID: 24026258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate.
    Tanaka Y; Suzuki M; Nakamura H; Toyoizumi S; Zwillich SH;
    Arthritis Care Res (Hoboken); 2011 Aug; 63(8):1150-8. PubMed ID: 21584942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials.
    Wallenstein GV; Kanik KS; Wilkinson B; Cohen S; Cutolo M; Fleischmann RM; Genovese MC; Gomez Reino J; Gruben D; Kremer J; Krishnaswami S; Lee EB; Pascual-Ramos V; Strand V; Zwillich SH
    Clin Exp Rheumatol; 2016; 34(3):430-42. PubMed ID: 27156561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs.
    Strand V; Kremer J; Wallenstein G; Kanik KS; Connell C; Gruben D; Zwillich SH; Fleischmann R
    Arthritis Res Ther; 2015 Nov; 17():307. PubMed ID: 26530039
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea.
    Lee MY; Park SK; Park SY; Byun JH; Lee SM; Ko SK; Lee EK
    Clin Ther; 2015 Aug; 37(8):1662-76.e2. PubMed ID: 26243076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
    Vieira MC; Zwillich SH; Jansen JP; Smiechowski B; Spurden D; Wallenstein GV
    Clin Ther; 2016 Dec; 38(12):2628-2641.e5. PubMed ID: 27889300
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study.
    Strand V; van der Heijde D; Tanaka Y; Keystone E; Kremer J; Zerbini CAF; Cardiel MH; Cohen S; Nash P; Song YW; Tegzová D; Gruben D; Wallenstein G; Connell CA; Fleischmann R;
    Clin Exp Rheumatol; 2020; 38(5):848-857. PubMed ID: 31858963
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.
    Mease P; Hall S; FitzGerald O; van der Heijde D; Merola JF; Avila-Zapata F; Cieślak D; Graham D; Wang C; Menon S; Hendrikx T; Kanik KS
    N Engl J Med; 2017 Oct; 377(16):1537-1550. PubMed ID: 29045212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study.
    van der Heijde D; Strand V; Tanaka Y; Keystone E; Kremer J; Zerbini CAF; Cardiel MH; Cohen S; Nash P; Song YW; Tegzová D; Gruben D; Wallenstein G; Connell CA; Fleischmann R;
    Arthritis Rheumatol; 2019 Jun; 71(6):878-891. PubMed ID: 30666826
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.
    Strand V; de Vlam K; Covarrubias-Cobos JA; Mease PJ; Gladman DD; Graham D; Wang C; Cappelleri JC; Hendrikx T; Hsu MA
    RMD Open; 2019; 5(1):e000806. PubMed ID: 30713721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness analysis of tofacitinib compared with adalimumab and etanercept in the treatment of severe active rheumatoid arthritis; Iranian experience.
    Fatemi B; Rezaei S; Taheri S; Peiravian F
    Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):775-784. PubMed ID: 33043757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy.
    Takeuchi T; Fleischmann R; Iikuni N; Shi H; Soma K; Paulissen J; Hirose T; Smolen JS
    Arthritis Res Ther; 2021 Aug; 23(1):220. PubMed ID: 34429160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
    Song GG; Choi SJ; Lee YH
    Int J Rheum Dis; 2019 Aug; 22(8):1563-1571. PubMed ID: 31211506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tofacitinib versus methotrexate in rheumatoid arthritis.
    Lee EB; Fleischmann R; Hall S; Wilkinson B; Bradley JD; Gruben D; Koncz T; Krishnaswami S; Wallenstein GV; Zang C; Zwillich SH; van Vollenhoven RF;
    N Engl J Med; 2014 Jun; 370(25):2377-86. PubMed ID: 24941177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study.
    Yamanaka H; Tanaka Y; Takeuchi T; Sugiyama N; Yuasa H; Toyoizumi S; Morishima Y; Hirose T; Zwillich S
    Arthritis Res Ther; 2016 Jan; 18():34. PubMed ID: 26818974
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies.
    Radominski SC; Cardiel MH; Citera G; Goecke A; Jaller JJ; Lomonte ABV; Miranda P; Velez P; Xibillé D; Kwok K; Rojo R; García EG
    Reumatol Clin; 2017; 13(4):201-209. PubMed ID: 27317492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.